From the National Center for Policy Analysis:
The effect of Obamacare on innovation within the health care sector is staggering. Scott Atlas, senior fellow at the Hoover Institution, explains how the law has begun to change research, development and innovation — activities which traditionally have taken place in the United States — thanks to the ACA’s $500 billion in new taxes, many of which fall on medical device and drug manufacturers. The result? Companies are moving overseas.